Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Empagliflozin 25 mg (Humanis) vs Jardiance in Healthy Volunteers
NCT06180109Phase 1Completed
- Sponsor
- Humanis
- Start
- Jul 2023
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of empagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Humanis. Primary endpoints: Maximum concentration obtained at 48 hours, AUC from 0 to infinity at 48 hours and 1 more. Started Jul 2023; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06180109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06180109.